A French prospective real-life cohort confirmed the favorable prognosis of nonmetastatic microsatellite instability (MSI) colorectal cancers. These cancers nevertheless entailed a high risk for recurrence in […]

Combining the bispecific antibody amivantamab (Rybrevant) with chemotherapy in the first- or second-line setting offers ongoing benefit to patients with epidermal growth factor receptor (EGFR)–mutated advanced […]

The investigational bispecific T-cell engager tarlatamab achieved durable responses and clinically meaningful survival outcomes in patients with small-cell lung cancer (SCLC), particularly at lower doses, according […]

(Reuters) -Novocure’s therapy met the main goal of a late-stage trial of slowing the progression of cancer to the brain in patients with a type of […]

A recent analysis identified significant disparities in survival outcomes as well as clinical and genetic features between Black and White women with a common subtype of […]

Screening for lung cancer can detect other health issues, as well. The reason is because the low-dose CT scans used for screening cover the lower neck […]

In the not-too-distant future, immunotherapy might be administered to cancer patients in their homes. The possibility is being driven by the development of subcutaneous formulations of […]

TOPLINE: Compared with chemotherapy, neoadjuvant chemoimmunotherapy led to better event-free survival and complete responses but not overall survival in patients with resectable non–small cell lung cancer […]

The combination of osimertinib (Tagrisso, AstraZenca) plus chemotherapy is associated with continued benefits in previously untreated advanced EGFR-mutated non–small-cell lung cancer (NSCLC) even after disease progression, […]